Suggested remit: To appraise the clinical and cost effectiveness of lenvatinib with pembrolizumab within its marketing authorisation for treating previously treated advanced, metastatic or recurrent endometrial cancer.
|
Status
|
In progress
|
|
Technology type
|
Medicine
|
|
Decision
|
Selected
|
| Process |
STA 2018
|
| ID number |
3811
|
Provisional Schedule
| Committee meeting: 1 |
09 August 2022 |
| Expected publication |
04 January 2023 |
Project Team
| Project lead |
Thomas Feist |
Email enquiries
| External Assessment Group |
Peninsula Technology Assessment Group (PenTAG), University of Exeter |
Stakeholders
| Companies sponsors |
Merck Sharpe Dohme |
| Others |
Department of Health and Social Care |
| |
Welsh Government |
| Patient carer groups |
Peaches Womb Cancer Trust |
| Professional groups |
Association of Physicians |
| |
Cancer Research UK |
| |
Royal College of Physicians |
| |
Royal College of Radiologists (RCR) |
| Comparator companies |
Eisai |
| General commentators |
All Wales Therapeutics and Toxicology Centre |
| |
British National Formulary |
| |
Department of Health and Social Services, Public Safety Northern Ireland |
| |
Healthcare Improvement Scotland |
| |
Scottish Medicine Consortium |
| |
Welsh Health Specialised Services Committee |
| |
Welsh Health Specialised Committee |
| Relevant research groups |
Institute of Cancer Research |
|
Date
|
Update
|
|
01 February 2022
|
Due to ERG capacity constraints, we are rescheduling the timeline for the appraisal of Pembrolizumab with lenvatinib for previously treated advanced, metastatic or recurrent endometrial cancer following the receipt of submissions in mid-February 2022. We will continue to assess the ERG capacity, and if an earlier slot becomes available, we will look to bring this topic forwards.
We anticipate that the appraisal will restart in mid-March 2022 when the submissions are sent over to the Evidence Review Group (ERG) and will be discussed at committee in early October 2022.
|
|
30 November 2021
|
Invitation to participate |
|
26 November 2021
|
Following recent discussions with the company for the appraisal of Lenvatinib with pembrolizumab for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811], please be advised that this topic will now be appraised as a Single Technology Appraisal and not a Multiple Technology Appraisal as previously advised.
For information, the appraisal is now anticipated to begin during late November 2021; with an anticipated evidence submission deadline to NICE of mid- February 2022. |
|
18 June 2021
|
Following recent discussions with the company for the appraisal of Lenvatinib with pembrolizumab for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811], please be advised that this topic will now be appraised as a Multiple Technology Appraisal.
For information, the appraisal is now anticipated to begin during late October 2021; with an anticipated evidence submission deadline to NICE of mid- February 2022.
|
|
16 November 2020 - 14 December 2020
|
Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators |
|
18 March 2019
|
In progress. DHSC referral received |
For further information on our processes and methods, please see our CHTE processes and methods manual